首頁 > 市場調查報告書 > 醫療設備

心血管設備

市場調查報告書

商品編碼

1373399

全球心臟瓣膜刀市場 - 2023-2030

Global Cardiac Valvulotome Market - 2023-2030

出版日期: 2023年10月18日 | 出版商:

DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

心臟瓣膜切開器是一種手術器械，用於在瓣膜成形術和瓣膜置換手術等醫療手術中切割或切開心臟瓣膜。

瓣膜切開術是一種使用瓣膜切開器來緩解瓣膜狹窄或逆流的外科手術。這是透過在受影響的瓣膜小葉中創建受控切口來完成的。這些切口可以擴大狹窄的瓣膜並改善其功能，這有助於恢復心臟內的正常血流。心臟外科醫師使用瓣膜刀來治療瓣膜相關疾病並改善心臟功能和患者福祉。

市場動態：促進因素與限制因素

主動脈瓣狹窄盛行率的增加預計將推動市場成長

使用心臟瓣膜切開器有助於治療主動脈瓣狹窄，這是一種導致主動脈瓣狹窄並阻礙血液從心臟左心室流向身體其他部位的疾病。當嚴重的主動脈瓣狹窄病例需要手術介入時，可以使用瓣膜切開術進行瓣膜切開術。

在這種醫療手術中，對主動脈瓣的厚瓣或融合瓣葉進行精確切割，以擴大其開口。這可以提高瓣膜的靈活性並減輕心臟的壓力，從而短期緩解胸痛和呼吸困難等症狀。然而，這可能不是一個永久的解決方案。

此外，歐洲心臟學會指出，主動脈瓣狹窄（AS）在65歲以下無先天性異常的人群中並不常見，但其盛行率隨著年齡的成長而增加。在美國，它是第二常見的瓣膜病變。 65歲時，約有5%的人口患有AS，且其盛行率隨著年齡的成長而顯著增加。

此外，根據最近的研究，大約 12.4% 的人口患有 AS，其中 3.4% 在 75 歲及以上的人口中出現嚴重症狀。 AS的盛行率隨著年齡的成長而顯著增加，從50-59歲年齡層的0.2%到80-89歲年齡層的9.8%不等。每年大約有千分之五的人會出現新的 AS 病例，這種情況通常發生在 60 歲左右的人群中。

對於患有臨床顯著的AS 的年輕人來說，二尖瓣主動脈瓣疾病很常見，而三尖瓣主動脈瓣狹窄在70 歲以上的老年人中更為普遍，通常需要主動脈瓣置換術。二葉式主動脈瓣並不罕見，大約有 0.5-0.8% 的人口患有這種情況。在高收入國家，AS 的負擔日益增加，預計到 2050 年，需要治療的老年患者（75 歲及以上有嚴重症狀的 AS）將顯著增加，在美國和歐洲將翻倍。預計到 2040 年，冰島 70 歲以上人口中嚴重 AS 的盛行率將增加一倍，到 2060 年將增加兩倍。

此外，包括瓣膜修復在內的心臟手術數量不斷增加，以及人們對心臟瓣膜疾病早期診斷和治療重要性的認知不斷提高，預計將在預測期內推動市場發展。

克制：

心臟瓣膜手術和相關手術費用昂貴，有出血、感染和附近結構損壞的潛在風險，而替代方案的可用性是預計在預測期內阻礙市場的因素。

Valvulotomy is a surgical procedure that uses a valvulotome to alleviate valve stenosis or regurgitation. This is done by creating controlled incisions in the affected valve leaflets. These incisions can widen narrowed valves and improve their functionality, which helps to restore proper blood flow within the heart. Cardiac surgeons use valvulotomes to treat valve-related diseases and improve cardiac function and patient well-being.

Market Dynamics: Drivers and Restraints

Increasing prevalence of aortic stenosis is expected to drive market growth

The use of a cardiac valvulotome can be beneficial in treating aortic stenosis, which is a condition that causes the aortic valve to narrow and impede the flow of blood from the heart's left ventricle to the rest of the body. When surgical intervention is necessary for severe cases of aortic stenosis, a valvulotomy procedure can be conducted using a valvulotome.

In this medical procedure, precise cuts are made in the thick or fused leaflets of the aortic valve to widen its opening. This improves the flexibility of the valve and reduces pressure on the heart, providing short-term relief from symptoms like chest pain and breathlessness. However, it may not be a permanent solution.

Moreover, the European Society of Cardiology states that Aortic stenosis (AS) is not very common in people under 65 years of age without a congenital abnormality, but its prevalence increases with age. In the United States, it is the second most common valvular lesion. At the age of 65, about 5% of the population has AS and its prevalence increases significantly with age.

In addition, according to recent studies, approximately 12.4% of the population has AS, with 3.4% experiencing severe symptoms among those aged 75 and older. The prevalence of AS increases significantly with age, ranging from 0.2% in the 50-59 age group to 9.8% in those aged 80-89 years. Around 5 in 1,000 individuals experience new cases of AS each year, and this typically occurs in people around the age of 60.

It is common for younger people with clinically significant AS to have bicuspid aortic valve disease, while tricuspid aortic valve stenosis becomes more prevalent in those over 70 years old, often requiring aortic valve replacement. Bicuspid aortic valves are not uncommon, occurring in approximately 0.5-0.8% of the population. In high-income countries, there is an increasing burden of AS, with a significant rise in elderly patients needing treatment (severe symptomatic AS aged 75 years and above) projected by 2050, doubling in both the USA and Europe. Iceland is also expected to have a doubling in the prevalence of severe AS among those aged ≥70 by 2040, with a tripling expected by 2060.

Furthermore, the rising number of cardiac surgeries, including valve repair, and increasing awareness of the importance of early diagnosis and treatment of heart valve conditions are the factors the market is expected to drive the market over the forecast period.

Restraint:

Cardiac valve surgeries and associated procedures are expensive, with potential risks of bleeding, infection, and damage to nearby structures, and the availability of alternatives are the factors expected to hamper the market over the forecast period.

Segment Analysis

The global cardiac valvulotome market is segmented based on product type, surgery type, end user, and region.

The Expandable Cardiac Valvulotome from the Product Type Segment Accounted for Approximately 37.6% of the Cardiac Valvulotome Market Share

Expandable cardiac valvulotomes are becoming more common in modern surgical practice. These devices offer flexibility and adjustability to surgeons and enable the controlled expansion or dilation of valve leaflets. They are precise and versatile, making them suitable for various valve-related procedures like valvuloplasty and valvulotomy. The expandable cardiac valvulotomes are particularly useful in treating valve stenosis and regurgitation.

Moreover, the increasing prevalence of valve diseases, the growing aging population, and advancements in cardiac surgery are the factors expected to drive the market over the forecast period.

For instance, advancements in cardiac surgery have led to the development of more sophisticated and precise instruments, such as Expandable Cardiac Valvulotomes. These tools play a crucial role in transcatheter aortic valve replacement (TAVR) procedures.

TAVR is a less intrusive method of treating aortic valve stenosis, which previously required open-heart surgery. This procedure involves using a catheter to deliver a collapsible artificial valve to the heart, typically through a small incision in the groin or chest.

Before the deployment of a new artificial valve, expandable cardiac valvulotomes are used to either predilate or enlarge the native aortic valve, guaranteeing a secure fit and optimal functionality. The use of instruments like expandable cardiac valvulotomes in TAVR, a minimally invasive procedure, minimizes patient trauma, shortens hospital stays, and speeds up recovery compared to traditional open-heart surgery. This innovation highlights how precise instruments are crucial in modern cardiac surgery, improving patient outcomes, and transforming treatment approaches for valvular heart diseases. Hence, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.

Geographical Analysis

North America accounted for approximately 40.3% of the market share in 2022

North America is expected to hold the largest market share owing to the presence of key players, and the increasing prevalence of valvular heart disease.

For instance, according to data from the Centers for Disease Control and Prevention (CDC), Americans suffer from valvular heart disease, and this number tends to increase among older adults. Among the population, approximately 1 in 40 people experience significant valvular heart disease. The mitral and aortic valves are most commonly affected, with around 4 million Americans experiencing significant mitral valve regurgitation. Additionally, roughly 250,000 new cases are diagnosed each year.

The statistics show that many patients require treatment for valvular heart diseases, with the mitral and aortic valves being particularly affected. This widespread occurrence of heart conditions is likely to increase the need for cardiac valvulotomes and other surgical interventions, leading to growth in the cardiac valvulotome market as healthcare providers work to find effective solutions for this common health problem. Hence, owing to the above factors, the North America region is expected to hold the largest market share over the forecast period.

COVID-19 Impact Analysis:

The COVID-19 pandemic significantly impacted the cardiac valvulotome market by leading to a reduction in the number of cardiac surgeries and valvulotomy procedures performed. For instance, a study was conducted in Lithuania to assess how the COVID-19 pandemic affected a cardiac surgery center's operations. The study revealed that the pandemic had a considerable impact on adult cardiac surgery, resulting in a decline in surgical procedures and a rise in mortality rates. Despite the increased risk of complications in COVID-19-positive patients, the study found that carrying out planned cardiac surgeries with appropriate protective measures during quarantine was a better alternative than completely halting elective cardiac surgeries.

Furthermore, the primary causes of this decrease were the reallocation of healthcare resources to address the surge in COVID-19 cases, the prioritization of critical care, and many patients' reluctance to seek medical attention for non-emergency conditions due to infection concerns. As a result, demand for valvulotomy procedures dropped temporarily, affecting the market. However, as healthcare systems gradually adjusted and resumed elective procedures, the market began to recover, highlighting the resilience of cardiac valvulotome procedures as necessary treatments for valvular heart diseases.

Competitive Landscape

The major global players in the cardiac valvulotome market include: LeMaitre Vascular, B. Braun SE, Andramed GmbH, LimFlow, Inc., Teleflex Incorporated, and Symmetry Surgical Inc. among others.

Why Purchase the Report?

To visualize the global cardiac valvulotome market segmentation based on product type, surgery type, end user and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of cardiac valvulotome market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global cardiac valvulotome market report would provide approximately 49 tables, 57 figures, and 170 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Surgery Type
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing prevalence of aortic stenosis
- 4.1.2. Restraints
  - 4.1.2.1. Risk associated with valvulotome
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Patent Analysis
5.7. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Expandable Cardiac Valvulotome*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Over the Wire Cardiac Valvulotome

8. By Surgery Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
- 8.1.2. Market Attractiveness Index, By Surgery Type
8.2. Valvulotomy*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Mitral Valve Commissurotomy
8.4. Aortic Valve Commissurotomy
8.5. Tricuspid Valve Commissurotomy
8.6. Others

9. By End User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ambulatory Surgical Center
9.4. Cardiac Surgery Centers
9.5. Cardiac Catheterization Labs
9.6. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. UK
  - 10.3.6.3. France
  - 10.3.6.4. Spain
  - 10.3.6.5. Italy
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. LeMaitre Vascular*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. B. Braun SE
12.3. Andramed GmbH
12.4. LimFlow, Inc.
12.5. Teleflex Incorporated
12.6. Symmetry Surgical Inc.

LIST NOT EXHAUSTIVE